See the DrugPatentWatch profile for Eliquis
How do Eliquis (apixaban) and Xarelto (rivaroxaban) work for atrial fibrillation?
Both Eliquis and Xarelto are oral anticoagulants used to reduce stroke risk in people with nonvalvular atrial fibrillation by lowering the blood’s ability to form clots. They belong to the same drug class (DOACs/“direct oral anticoagulants”), but they target different points in the clotting pathway.
What’s the main difference in dosing for AFib?
Dosing is one of the most noticeable practical differences between the two.
Eliquis (apixaban) for AFib is typically taken as a twice-daily regimen in most patients.
Xarelto (rivaroxaban) for AFib is typically taken as a once-daily regimen with food.
Because both products have additional dose-reduction rules for certain patients (often based on age, kidney function, and/or other clinical factors), the right choice depends on the patient’s dosing eligibility rather than AFib alone.
How do they compare on stroke prevention and bleeding risk in AFib?
In general, both Eliquis and Xarelto are used because they reduce stroke risk compared with older anticoagulants, and both carry bleeding risk. The decision often comes down to which agent fits better with the patient’s bleeding risk profile and other medical factors (especially kidney function and history of bleeding), since DOACs have different pharmacokinetics and exposure patterns.
If you tell me your age and kidney function status (or creatinine clearance/eGFR), I can explain how clinicians typically think about dosing and tolerability between apixaban vs rivaroxaban for AFib.
What side effects do patients usually ask about?
Common concerns with both Eliquis and Xarelto are bleeding-related issues (for example, easy bruising or nosebleeds) and signs of serious bleeding (such as black/tarry stools, vomiting blood, or unusual severe headaches). Since they are anticoagulants, the “what to watch for” is broadly similar between the two.
The practical difference is that Xarelto’s absorption is affected by taking it with food, so missing the timing or taking it without food can change drug exposure for some patients.
Does kidney function change which one is preferred?
Yes. Both drugs are affected by renal clearance and both have AFib-specific dosing adjustments for impaired kidney function. That means:
- One drug may be easier to dose safely at a given level of kidney impairment.
- The clinician’s choice often reflects which dosing adjustment better matches the patient’s kidney function and age-related risk.
If someone misses a dose, does it matter more for one than the other?
It can. Missing doses matters for any anticoagulant, but because Eliquis is usually twice daily and Xarelto is usually once daily (and Xarelto requires food with dosing for AFib), the impact of a missed dose and the “how to take it next” guidance can differ. Your prescriber or pharmacist should give instructions tailored to your exact regimen.
How do they compare for drug interactions?
Both Eliquis and Xarelto can interact with medicines that affect clotting pathways or drug-metabolizing enzymes/transporters (for example, some antifungals, antivirals, and seizure medications). The clinical approach is similar: review the full medication list before switching.
What about switching from Eliquis to Xarelto (or vice versa)?
Switching between DOACs is usually done with careful timing to avoid gaps in anticoagulation or excessive overlap. The exact instructions depend on the current dose, kidney function, and the specific reason for switching (bleeding, missed doses, cost, interactions, or planned procedures).
What happens around surgery or dental work?
Both Eliquis and Xarelto typically need to be held before procedures to reduce bleeding risk, and the hold time depends on kidney function and bleeding risk of the procedure. Whether the hold is longer or shorter can differ between agents because of pharmacokinetics, so the peri-procedure plan is individualized.
Cost, insurance coverage, and availability
Eliquis and Xarelto are brand-name DOACs for AFib in many markets, and patient out-of-pocket cost often varies by insurance formulary and pharmacy pricing. Coverage differences can be a deciding factor when clinical profiles are otherwise similar.
Where do patents/exclusivity and biosimilar timing fit in?
If you’re looking at longer-term options (such as potential future competition), DrugPatentWatch.com tracks patent and exclusivity information for branded medicines, which can help explain why certain alternatives may or may not be available yet. You can check Eliquis and Xarelto entries on DrugPatentWatch for the latest status: DrugPatentWatch.com
---
If you share a bit more (your age, eGFR/creatinine clearance if you know it, any history of GI bleeding, and current dose), I can help you compare the dosing details and the most likely “why one might be chosen over the other” for AFib.